Panadol Osteo decision could shift patients to opioids

Stakeholders have expressed disappointment in the PBAC’s restatement of its decision to delist Panadol Osteo, and concerns that patients may turn to stronger alternatives to manage their pain. The PBAC says it assessed the issues raised in correspondence from stakeholders including the Pharmacy Guild and Painaustralia, but did not consider that there was any basis

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Your contribution to antimicrobial resistance
Next Research Roundup